PMID- 37366247 OWN - NLM STAT- MEDLINE DCOM- 20230915 LR - 20230916 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 16 DP - 2023 Aug TI - The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: A population-based study. PG - 16697-16706 LID - 10.1002/cam4.6292 [doi] AB - BACKGROUNDS: The role of cytoreductive radical prostatectomy (cRP) for bone-metastatic prostate cancer (bmPCa) remains controversial. We aimed to figure out whether cRP and lymph node dissection (LND) can benefit bmPCa. METHODS: 11,271 PCa patients with bone metastatic burden from 2010 to 2019 were identified using SEER-Medicare. Overall survival (OS) and cancer-specific survival (CSS) rates were visualized using Kaplan-Meier plots. Multivariable Cox regression analyses were constructed to examine the effects of cRP and LND on survival, after stratifying to age, prostate specific antigen (PSA), clinical stages, Gleason score, metastatic burden, radiotherapy, and chemotherapy status. RESULTS: 317 PCa patients underwent cRP and cRP was increasingly performed for bmPCa from 2010 (2.2%) to 2019 (3.0%) (p < 0.05). In multi analyses, cRP was predisposed to a better OS or CSS in patients with age < 75, PSA < 98 ng/mL, bone-only metastatic sites or patients not receiving chemotherapy (all p < 0.05). For the patients undergoing cRP, LND especially extended LND was associated with a better OS or CSS (all p < 0.05). CONCLUSIONS: cRP might benefit OS or CSS in young patients with low PSA and bone-only metastatic sites not receiving chemotherapy. And a clear OS or CSS benefit of LND especially extended LND was observed in patients undergoing cRP. CI - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Zhai, Tingshuai AU - Zhai T AUID- ORCID: 0000-0002-1441-6256 AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Ma, Jinliang AU - Ma J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Liu, Yi AU - Liu Y AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Li, Haitao AU - Li H AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Peng, Yanli AU - Peng Y AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Guo, Wenmin AU - Guo W AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Jia, Jiedong AU - Jia J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Wu, Xiaolin AU - Wu X AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Jiang, Huanrong AU - Jiang H AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Tian, Jun AU - Tian J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Wang, Dongwen AU - Wang D AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230627 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - Male MH - Humans MH - Aged MH - United States MH - Prostate-Specific Antigen MH - Lymph Nodes/pathology MH - Cytoreduction Surgical Procedures MH - Treatment Outcome MH - Medicare MH - Lymph Node Excision MH - *Prostatic Neoplasms/pathology MH - Prostatectomy/adverse effects MH - *Bone Neoplasms/secondary PMC - PMC10501265 OTO - NOTNLM OT - SEER-Medicare OT - bone metastases OT - cytoreductive radical prostatectomy OT - lymph node dissection OT - prostate cancer OT - survival analysis COIS- The authors have no conflict of interest to declare. EDAT- 2023/06/27 13:11 MHDA- 2023/09/15 06:42 PMCR- 2023/06/27 CRDT- 2023/06/27 06:43 PHST- 2023/06/06 00:00 [revised] PHST- 2023/01/24 00:00 [received] PHST- 2023/06/15 00:00 [accepted] PHST- 2023/09/15 06:42 [medline] PHST- 2023/06/27 13:11 [pubmed] PHST- 2023/06/27 06:43 [entrez] PHST- 2023/06/27 00:00 [pmc-release] AID - CAM46292 [pii] AID - 10.1002/cam4.6292 [doi] PST - ppublish SO - Cancer Med. 2023 Aug;12(16):16697-16706. doi: 10.1002/cam4.6292. Epub 2023 Jun 27.